Treatment outcomes of early stage endometrial cancer patients: single center experience

Year 2019, Volume: 44 Issue: 3, 861 - 865, 30.09.2019

Ali Murat Sedef , Didem Karaduman Ali Ayberk Besen , Hüseyin Mertsoylu , Fatih Köse

https://doi.org/10.17826/cumj.491549

Abstract

Purpose:Endometrium cancers are the most common
gynecological cancer type in women. Surgery is the standard treatment for women
with early stage endometrial cancer patients. The adjuvant treatment of early
stage endometrial cancer is based on the risk and expected type (local vs
systemic) of relapse. In this study, we evaluated clinicopathological
characteristics and treatment outcomes of endometrial cancer patients in our
center.

Materials and Methods:This study was a hospital-based retrospective
observational case-series study. 116 patients were included in the study from Baskent University Department of Medical
Oncology and Gynecological Oncology between the years of 2009-2015. De-novo metastatic
patients were not included in the study. 

Results:The
median age of the patients was 58 (range 27-81) years. All of patients had
European Cooperative Oncology Group (ECOG) performance score 0 (n:116). Endometrioid
histology was the most common histopathological subtype (n:103, 88%). All
of the patients were in local and local advanced stage. The
significant percentage of patients had grade 2 tumor (n:55, 47.4%). Myometrial
invasion was less than 50% in 78 patients (67.2 %). The median follow-up time
was 61 months and 8 (6.9%) patients died. All patients underwent standard
surgical staging with standard lymphadenectomy. Overall survival (OS) was not
reached. There were 14 patients (12.1 %) and 34 patients (29.3 %) treated with
adjuvant chemotherapy and radiotherapy, respectively.

Conclusion:Though endometrial cancer is the most common
gynecological tumors in women, cure rate is very high. Relapse rate was 6 % (7
patients) and most of the relapse were local, 71.4% (5 patients).

Keywords

Endometrium cancer, basal clinicopathological characteristics, treatment outcomes

Erken evre endometrium kanseri tanılı hastaların tedavi sonuçları: tek merkez deneyimi

Abstract

kanser hastalarının klinikopatolojik özelliklerini ve tedavi sonuçlarını değerlendirilmesi amaçlanmıştır.

Gereç ve Yöntem: Bu çalışma hastane bazlı retrospektif gözlemsel bir vaka serileri çalışmasıdır. 2009-2015 yılları arasında Başkent Üniversitesi Tıbbi Onkoloji ve Jinekolojik Onkoloji Anabilim Dallarına başvuran 116 hasta dahil edildi. De-novo metastatik hastalar çalışmaya dahil edilmedi.

Bulgular: Hastaların medyan yaşı 58 (dağılım 27-81) idi. Hastaların hepsinin ECOG performans puanı 0 (n: 116) idi. Endometrioid histoloji en sık görülen histopatolojik alt tipti (n: 103,% 88). Tüm hastalar lokal ve lokal ileri evrede idi. Hastaların önemli oranda bir kısmının grade 2 tümörü vardı (n: 55,% 47.4). Myometrial invazyon 78 hastada (% 67.2)% 50'den azdı. Ortanca takip süresi 61 ay idi ve 8 (% 6.9) hasta öldü. Tüm hastalara standart lenfadenektomi ile standart cerrahi evreleme yapıldı. Median genel sağkalım süresine (OS) ulaşılamadı. Sırasıyla 14 hasta (% 12.1) ve 34 hasta (% 29.3) adjuvan kemoterapi ve radyoterapi ile tedavi edildi.

Sonuç: Endometrial kanser kadınlarda en sık görülen jinekolojik tümörler olmasına rağmen, tedavi oranı çok yüksektir. Nüks oranı % 6 (7 hasta) idi ve nüksün çoğu lokal,% 71.4 (5 hasta) idi.

Keywords

Endometrium kanseri, bazal klinikopatolojik özellikler, tedavi sonuçları

References

• Referans 1: American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106:413.
• Referans 2:Kimura T, Kamiura S, Yamamoto T, et al. Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 2004; 85:145.
• Referans 3:Seebacher V, Schmid M, Polterauer S, et al. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer 2009; 9:460.
• Referans 4: Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.
• Referans 5:Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:55.
• Referans 6: Eifel PJ, Ross J, Hendrickson M, et al. Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 1983; 52:1026.
• Referans 7: Straughn JM Jr, Huh WK, Kelly FJ, et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol 2002; 84:194.